Phaseline

Targets › MAGE-A8

MAGE-A8: drug programs, companies and trials

1 program from 1 company in 2 trials: 2 Phase 1; Oncology; next expected readout Sep 2027.

Open in Phaseline: the race on MAGE-A8, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Immatics BiotechnologiesIMA401
TCER® (T cell engineered receptor) targeting MAGE-A4 and/or MAGE-A8
MAGE-A4, MAGE-A8Phase 1Refractory CancerSep 2027

Conditions

Refractory Cancer (2)

Modalities

mixed (1)

Companies

Immatics Biotechnologies (1)

Related targets

MAGE-A4 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.